Abstract Number: 1797 • 2018 ACR/ARHP Annual Meeting
An Update on Pulmonary Artery Involvement in Behcet’s Syndrome: More Pulmonary Artery Thrombotic Disease and a Better Outcome
Background/Purpose: Pulmonary artery involvement (PAI) is the most common form of arterial involvement in Behçet’s syndrome (BS). A previous survey (1) by our group had…Abstract Number: 1975 • 2018 ACR/ARHP Annual Meeting
Behcet’s Disease Lies in the “B” Holder. New Associations in Disease Susceptibility and Manifestations
Background/Purpose: Behçet’s disease is a multisystem disease affecting young adults with variable vessel vasculitis as its underlying pathology. Previous studies in Behçet’s disease linked it…Abstract Number: 1798 • 2018 ACR/ARHP Annual Meeting
Leg Ulcers in Behçet’s Syndrome: An Observational Survey in 24 Patients
Background/Purpose: Formal experience with leg ulcers in Behcet’s syndrome (BS) is limited. It is a relatively rare complication that can be seen during the course…Abstract Number: 2166 • 2018 ACR/ARHP Annual Meeting
Treatment of Venous Thrombotic Events in Behçet Disease: A Systematic Literature Review
Background/Purpose: Venous thrombosis (VT) is a serious and potentially life-threatening manifestation of Behçet disease (BD). However, there is little evidence of the management of the…Abstract Number: 1799 • 2018 ACR/ARHP Annual Meeting
Increased Vein Wall Thickness in Behçet’s Syndrome
Background/Purpose: Lower extremity vein thrombosis (LEVT) is the key feature of vascular involvement in Behçet’s syndrome (BS).Vein wall thickness (VWT) is proposed to be a…Abstract Number: 2269 • 2018 ACR/ARHP Annual Meeting
Infliximab Therapy in Refractory Retinal Vasculitis of Behçet’s Disease, Short and Long-Term Follow-up. Multicenter Study of 72 Patients
Background/Purpose: Retinal vasculitis is a serious complication of uveitis due to Behçet’s disease (BD). The treatment is based on corticosteroids, conventional immunosuppressants (IS) and anti-TNF-α…Abstract Number: 1801 • 2018 ACR/ARHP Annual Meeting
Factors Associated with Damage Progression in Behçet’s Syndrome Uveitis
Background/Purpose: Uveitis in Behçet’s syndrome (BS) follows a recurrent disease course with inflammatory exacerbations causing damage in the uvea, retina and optic nerve even with…Abstract Number: 2789 • 2018 ACR/ARHP Annual Meeting
Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 28 Weeks: Results from a Phase III Study
Background/Purpose: Behçet’s syndrome is a chronic, relapsing, multi-system inflammatory disorder characterized by recurrent oral ulcers (OU), which can be disabling and substantially impact quality of…Abstract Number: 1802 • 2018 ACR/ARHP Annual Meeting
Behcet’s Disease in the Southwestern United States
Background/Purpose: Behcet’s disease (BD) in the US is estimated to have a prevalence of 5.2-6.6 per 100,000 populations which is similar to that of European…Abstract Number: 2841 • 2018 ACR/ARHP Annual Meeting
Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup
Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in a global, phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with Behçet’s syndrome and…Abstract Number: 149 • 2018 ACR/ARHP Annual Meeting
Deep Immune-Profiling of CD4+ T Cells in Behçet’s Disease
Background/Purpose: Functionality and immune-phenotypes of the human CD4+ T-cell compartment in Behçet’s disease (BD) are under-investigated, but several lines of evidence point to its relevance…Abstract Number: 1804 • 2018 ACR/ARHP Annual Meeting
Optimization Protocol for Adalimumab Treatment in Refractory Uveitis Due to Behçet’s Disease
Background/Purpose: Uveitis is the most common ocular manifestation in Behçet Disease (BD), which can cause irreversible blindness. Once the efficacy, safety and cost-effectiveness of Adalimumab…Abstract Number: 2993 • 2018 ACR/ARHP Annual Meeting
Vascular Involvement in Behcet’s Syndrome May be Associated with Subclinical Atherosclerosis
Background/Purpose: Behçet's Syndrome (BS) is a vasculitic process which is characterized by recurrent oral and genital aphthous ulcerations, ocular, vascular, neurological, and gastrointestinal involvement .…Abstract Number: 918 • 2018 ACR/ARHP Annual Meeting
A Novel Familial RELA Truncation Is Associated with Behçet’s-like Mucocutaneous Ulceration Syndrome
Background/Purpose: Bechet’s disease (BD) is a heterogeneous multifactorial auto-inflammatory condition characterized by recurrent episodes of oral and genital ulceration, uveitis and skin lesions, with less…Abstract Number: 1805 • 2018 ACR/ARHP Annual Meeting
Strong Association of HLA-DRB1*0901 with Japanese Patients with Chronic Progressive Neuro-Behçet’s Disease
Background/Purpose: Central nervous system involvement is one of the most serious complications in Behçetfs disease (BD). This condition is referred to as neuro-BD (NB) and…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »